Semax 10mg

Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). It was developed by Russian scientists in the 1980s and has been used in Russia and Ukraine for various neurological conditions, including stroke and cognitive disorders.

How Does Semax Work?

Semax is designed to cross the blood-brain barrier and exert its effects directly on the brain. It is believed to work through several mechanisms:

• Neurotrophic Factor Upregulation: Semax increases levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are essential for neuronal growth and survival.
• Neurotransmitter Modulation: It may influence the activity of neurotransmitters like dopamine, serotonin, and enkephalin, which are involved in mood, cognition, and pain perception.

Potential Benefits of Semax

• Neuroprotection: Semax may protect neurons from damage caused by various factors, such as stroke, trauma, and neurodegenerative diseases.
• Cognitive Enhancement: It may improve cognitive functions like memory, attention, and learning.
• Mood Regulation: Semax may have mood-stabilizing effects by modulating neurotransmitter levels.
• Pain Relief: It may alleviate pain by interacting with opioid receptors.

Semax has shown promise in various neurological conditions. It’s particularly recognized for its neuroprotective and neuroregenerative properties.

Neuroprotective Effects

• Stroke: Semax has been studied in stroke patients, where it has shown potential to improve motor function, cognitive abilities, and reduce inflammation.
• Neurodegenerative Diseases: Research suggests that Semax may be beneficial for conditions like Alzheimer’s disease and Parkinson’s disease, as it can protect neurons from damage and promote neurogenesis.
• Brain Injury: Semax may help protect the brain from damage caused by traumatic brain injury.
• Glaucoma: Some studies suggest that Semax may protect against pressure-induced nerve damage in glaucoma patients.

Mechanisms of Action

Semax exerts its neuroprotective effects through various mechanisms:

• Neurotrophic Factor Upregulation: It increases levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are essential for neuronal growth and survival.
• Neurotransmitter Modulation: Semax may influence the activity of neurotransmitters like dopamine, serotonin, and enkephalin, which are involved in mood, cognition, and pain perception.
• Anti-inflammatory Effects: It may reduce inflammation in the brain, which can contribute to neurodegenerative diseases.
• Improved Blood Flow: Semax may improve blood flow to the brain, providing essential nutrients and oxygen.

Future Research

While Semax has shown promising results, further research is needed to fully understand its mechanisms of action and long-term effects. Clinical trials with larger sample sizes and longer durations are necessary to confirm its efficacy and safety.

References

1. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. Published 2014 Nov 19. doi:10.3390/molecules191119066
3. Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. doi:10.4103/1673-5374.320969
4. Knezevic M, Gojkovic S, Krezic I, et al. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines. 2021;9(6):609. Published 2021 May 26. doi:10.3390/biomedicines9060609
5. Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. Published 2020 Oct 13. doi:10.1038/s41598-020-74022-y
6. Lozic M, Stambolija V, Krezic I, et al. In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro. Emerg Med Int. 2020;2020:6805354. Published 2020 May 27. doi:10.1155/2020/6805354
7. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
8. Harty PS, Zabriskie HA, Erickson JL, Molling PE, Kerksick CM, Jagim AR. Multi-ingredient pre-workout supplements, safety implications, and performance outcomes: a brief review. J Int Soc Sports Nutr. 2018;15(1):41. Published 2018 Aug 8. doi:10.1186/s12970-018-0247-6
9. Sikiric P, Drmic D, Sever M, et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020;26(25):2991-3000. doi:10.2174/1381612826666200424180139
10. Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020;26(25):2971-2981. doi:10.2174/1381612826666200523180301
11. National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957. https://pubchem.ncbi.nlm.nih.gov/compound/Bpc-157. Accessed Sept. 10, 2021.
12. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Rak D, Dzidic S, Vrcic H, Sebecic B. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83. doi: 10.2174/13816128130111. PMID: 22950504.
13. Strinic D, Belosic Halle Z, Luetic K, Nedic A, Petrovic I, Sucic M, Zivanovic Posilovic G, Balenovic D, Strbe S, Udovicic M, Drmic D, Stupnisek M, Lovric Bencic M, Seiwerth S, Sikiric P. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sci. 2017 Oct 1;186:66-79. doi: 10.1016/j.lfs.2017.08.006. Epub 2017 Aug 7. PMID: 28797793.
14. Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, Seiwerth S, Mise S, Turkovic B, Dodig G, Miklic P, Buljat G, Prkacin I. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol. 1999 Aug 20;379(1):19-31. doi: 10.1016/s0014-2999(99)00486-0. PMID: 10499368.
15. United States Anti-Doping Agency. BPC-157: experimental peptide creates risk for athletes. USADA website. https://www.usada.org/spirit-of-sport/education/bpc-157-peptide-risk/